VANDA PHARMACEUTICALS INC. Net Change in Cash
VANDA PHARMACEUTICALS INC. (VNDA) reported Net Change in Cash of -$28.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$30.82M, a 425.07% decline year-over-year.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $9.48M.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$10.66M, a 104.87% decline year-over-year.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $219.14M, a 1375.21% increase year-over-year.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$17.46M.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$33.51M, a 4330.43% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $792.00K, a 99.04% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $82.91M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.97M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$30.82M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$17.46M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | -$32.29M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | -$21.33M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $9.48M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$33.51M 10-K · filed 2026-02-12 | |||
| 2024-09-30 | -$35.32M 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | -$32.87M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | -$10.66M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $792.00K 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $48.16M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $15.00M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $219.14M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $82.91M 10-K · filed 2025-02-14 | |||
| 2022-09-30 | -$2.72M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $6.15M 10-Q · filed 2023-07-28 | |||
| 2022-03-31 | $14.86M 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | -$9.02M 10-K · filed 2024-02-08 | |||
| 2021-09-30 | -$10.57M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$3.79M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $11.10M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $15.96M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | $11.90M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $50.23M 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | $19.88M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$16.10M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$21.80M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | -$14.46M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$26.63M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $27.41M 10-K · filed 2021-02-11 | |||
| 2018-09-30 | $27.19M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $27.30M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $121.70M 10-Q · filed 2019-05-03 | |||
| 2017-12-31 | -$6.92M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | -$17.84M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | -$26.19M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | -$20.32M 10-Q · filed 2018-05-02 | |||
| 2016-12-31 | -$10.37M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |